PTPRC and neoplasm: The flow cytometry analysis revealed that MDCa@RBC‐Alipo nanobiologics effectively enhanced the frequency of tumor‐infiltrating CD45+CD11b+F4/80+ macrophages compared with other controls (Figure 5G,H).